Acumen Pharmaceuticals Demonstrates 68-Fold Increase in Brain Delivery for Alzheimer's Antibody Using Novel Transferrin Receptor Technology
核心洞察
Acumen Pharmaceuticals and JCR Pharmaceuticals (搜索) demonstrated 15 to 68-fold increases in brain penetration for Alzheimer's antibodies using transferrin receptor (搜索) technology, addressing the critical challenge that typically less than 1% of intravenous antibodies reach the brain.
The enhanced brain delivery technology preserved the potency and selectivity of sabirnetug (ACU193) for toxic amyloid beta oligomers (搜索) in mouse models while potentially limiting exposure to vascular amyloid.
Analysis of the Phase 2 ALTITUDE-AD trial recruitment data revealed that site databases and physician referrals were the most effective methods among six strategies tested, with 542 patients enrolled from 2,362 screened across 76 sites.
Acumen Pharmaceuticals announced breakthrough research demonstrating dramatically improved brain delivery of Alzheimer's disease (搜索) antibodies at the 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference. The collaborative study with JCR Pharmaceuticals (搜索) showed that fusion proteins combining transferrin receptor (搜索) (TfR) technology with amyloid beta oligomer-targeting antibodies achieved 15 to 68-fold increases in brain penetration in mice.
Enhanced Brain Delivery Addresses Critical Limitation
The research addresses a fundamental challenge in Alzheimer's drug development: poor brain penetration of therapeutic antibodies. Intravenous delivery of IgG antibodies typically results in less than 1% of the delivered dose reaching the brain, significantly limiting therapeutic potential.
To overcome this barrier, researchers fused murine TfR-binding antibody fragments from JCR's J-Brain Cargo® platform with ACU193 (sabirnetug) and ACU234 (搜索), monoclonal IgG2 antibodies targeting soluble amyloid beta oligomer (AβO) species. The resulting fusion proteins maintained their potency and selectivity for soluble AβO species in mouse models of Alzheimer's disease (搜索) while achieving the dramatic increase in brain penetration.
"This research is advancing the understanding of two major challenges in the treatment of Alzheimer's disease (搜索) – targeted drug delivery into the CNS and clinical trial execution," said Jim Doherty, PhD, President and Chief Development Officer of Acumen Pharmaceuticals.
Transferrin Receptor Pathway Shows Promise
TfR-mediated transcytosis offers the potential to enhance brain levels of soluble AβO-targeting antibodies while simultaneously limiting exposure to vascular amyloid found primarily in cerebral arteries. This dual benefit could maximize the efficacy-to-safety ratio of Alzheimer's treatments.
Building on these promising results, Acumen and JCR Pharmaceuticals (搜索) are now developing TfR-targeting antibodies for clinical testing. The J-Brain Cargo® platform has already demonstrated clinical success, with IZCARGO® (pabinafusp alfa) approved in Japan for treating a lysosomal storage disorder.
ALTITUDE-AD Trial Reveals Optimal Recruitment Strategies
Separately, Acumen shared insights from recruitment data analysis of its Phase 2 ALTITUDE-AD trial to help optimize early Alzheimer's disease (搜索) trial enrollment. The study tracked 2,362 participants screened across 76 sites, with 542 ultimately enrolled.
Of six recruitment methods utilized, site databases and physician referrals proved most effective due to established relationships and pre-screened eligibility. These findings provide actionable insights for improving trial recruitment efficiency and reducing screen failure rates in future early Alzheimer's disease (搜索) studies.
Sabirnetug Targets Toxic Oligomers
Sabirnetug (ACU193) is a humanized monoclonal antibody designed with selectivity for soluble amyloid beta oligomers (搜索), which are highly toxic and pathogenic forms of amyloid beta relative to monomers and plaques. Soluble AβOs are potent neurotoxins that bind to neurons, inhibit synaptic function, and induce neurodegeneration.
The antibody has received Fast Track designation from the U.S. Food and Drug Administration for treating early Alzheimer's disease (搜索). The ongoing Phase 2 ALTITUDE-AD trial is a multi-center, randomized, double-blind, placebo-controlled study evaluating sabirnetug infusions administered once every four weeks in slowing cognitive and functional decline compared to placebo in participants with early Alzheimer's disease.
The trial, initiated in 2024, enrolled 542 individuals with early Alzheimer's disease (搜索) at sites in the United States, Canada, the European Union, and the United Kingdom. The study follows positive results from the Phase 1 INTERCEPT-AD trial.